Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: June Update

Performance overview

Value at beginning of month: $140,475.45

Value at end of month: $150,941.05

Month over month change: +7.45%

Total IRR: 18.21%

Related indices, monthly change

NASDAQ: +7.42%

IVV (iShares Core S&P 500): +6.94%

IBB (iShares NASDAQ Biotechnology Index): +9.21%

MXI (iShares Global Materials): +10.34%

VEGI (iShares MSCI Global Agriculture Producers): +9.25%

ICLN (iShares Clean Energy): +7.25%

Individual performances


Intrexon had a particularly strong performance due to an announced partnership for cannabinoid production as well as positive clinical trial news for a microbe-based diabetes treatment. Kraig Biocraft Laboratories had a second great month in a row as well. The only company that had a really bad month was Arcadia Biosciences, who were down over 40% thanks to having to raise additional funds.

Changes made to index


You can view the index here.

Allocation as of June 29, 2019


Calvin Schmidt Synthetic Biology Index: May Update